Final Report - India Cohort Analysis: A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine Given in a Series of 3 Infant Doses and 1 Toddler Dose in Infants in Ind

Final Report - India Cohort Analysis: A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine Given in a Series of 3 Infant Doses and 1 Toddler Dose in Infants in India and Taiwan lul46 Tue, 09/22/2026 - 03:10 Prevnar 20®/Prevenar 20® 20-Valent Pneumococcal Conjugate Vaccine (20vPnC), Compound Number: PF-06482077 PHASE III Fri, 09/16/2022 - 12:00 Sat, 09/20/2025 - 12:00 NCT05512819 B7471024 Public Disclosure Synopsis merged cohorts.pdf (2.39 MB) N https://clinicaltrials.gov/study/NCT05512819?term=B7471024 viewType=Card rank=1 B7471024 — Company newsroom — sourced from Pfizer. Matter furnished by the company. Not a Notice Nearby paid placement. This page reprints matter furnished by the company from its official newsroom. Notice Nearby did not write this release. Read the original: https://www.pfizer.com/node/563621